Edesa Biotech Files IND Application for Phase 2/3 COVID-19 Study
clinical study of its investigational drug, EB05, for the treatment of hospitalized COVID-19 patients.
The company recently received expedited approval to begin the Phase 2/3 study in Canada and is seeking government grants to accelerate site selection and initiate patient enrollment
The safety and tolerability of EB05 has been demonstrated in more than 120 subjects.
The company plans to enroll up to 450 patients in the first phase of the trial.